Evasion of immune T cell responses is crucial for persistent viruses to
I
nfection with Kaposi's sarcoma-associated herpesvirus (KSHV) results in a lifelong carriage state, usually with little harmful effect. However, the virus can cause Kaposi's sarcoma, an AIDSassociated malignancy, and has been proposed to be the etiological agent of primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD) (1) (2) (3) (4) . KSHV can establish latent infections in the B cell compartment and has the potential to transform cell growth (5) , a property that is relevant to its mechanisms of persistence in immunocompetent hosts as well as its oncogenic potential.
Successful persistence of viral infection depends on the establishment of a balance between host immune responses and viral immune evasion. The innate immune system provides an immediate defense against infection and is very important for controlling viral infections. Remarkably, KSHV encodes four proteins named virus-encoded interferon regulatory factors (vIRFs) that are homologues of cellular IRFs. The vIRFs have been shown to inhibit IFN responses (6) . With regard to adaptive immune responses, KSHV genes reported to modulate major histocompatibility complex class I (MHC-I) antigen presentation include K3 and K5 (7, 8) . However, KSHV is poorly understood in terms of its interference with the MHC-II antigen presentation pathway.
Mechanisms for interfering with the MHC-II antigen presentation pathway have been reported for other herpesviruses and involve multiple points on the MHC class II antigen presentation pathway (9) . For example, US2 (10), US3 (11) , and pp65 (12) of human cytomegalovirus (HCMV) and glycoprotein B of human herpes simplex virus 1 (13) all target the HLA-DR molecule for diversion and/or degradation during membrane transport. More recently, Epstein-Barr virus (EBV)-encoded BZLF1 has been shown to target CD74, the invariant-chain chaperone of HLA-DR, to evade CD4 T cell recognition (14) . The gp42 protein of EBV also binds to MHC-II to sterically inhibit CD4 T cell receptor interactions (15) .
Using peripheral blood mononuclear cells from healthy KSHV-infected donors, Sabbah et al. successfully identified and isolated CD4 T cell responses to LANA, a protein expressed in all KSHV-infected cells, whether normal or malignant. However, most PEL cell lines were not be able to be recognized by these CD4 T cell clones, except via reexpression of the MHC class II transactivator (CIITA) in the PELs (16) . A study from another group showed that vIRF3 can inhibit the PIII and PIV promoters of CIITA and can inhibit the transcription and translation of MHC-II elements (17) , which provides a potential explanation for the poor recognition of PELs by the LANA-specific CD4 T cells. However, the small MHC-II downregulation observed in the lat-ter study cannot fully explain the substantially reduced MHC-II expression observed in the PELs. There is also no direct evidence that this inhibition of transcription of CIITA by vIRF3 can impair the recognition by CD4 T cells.
In the study described here, we have carried out a more detailed analysis of the effects of vIRF3 on MHC-II antigen presentation and, importantly, have extended the work to include functional T cell recognition assays as a readout. We demonstrate for the first time that vIRF3 does indeed impair the recognition by KSHVspecific CD4 T cells in B cells and PEL lines and that the ability of PEL cells to be recognized by LANA-specific CD4 T cells correlated with vIRF3 expression at the single-cell level. Using quantitative reverse transcription-PCR (RT-PCR), we demonstrate that vIRF3 can inhibit the transcription of CIITA and MHC-II elements, through which vIRF3 can substantially downregulate MHC-II expression, but with slow kinetics that lag behind an effect on functional presentation of antigen to CD4 T cells. The data reveal additional mechanisms of impairment of MHC-II antigen presentation by vIRF3 which are partly mediated through a CTIIA-independent inhibition of the transcription of MHC-II elements.
MATERIALS AND METHODS
Plasmids and transfection. The vIRF3 gene was subcloned into the EcoRI/XhoI sites of the pCDNA3-IRES-nls-GFP plasmid vector and was verified by restriction digestion and sequence analysis. The pCDNA3-cyto-EBNA1 plasmid was kindly provided by Graham Taylor (18) . The Mel JuSol (MJS) melanoma-derived cell line (19) was maintained in RPMI 1640 medium (Gibco BRL) supplemented with 10% fetal calf serum (FCS). Transient transfection of MJS cells with plasmid DNA was routinely performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Targets for the T cell recognition assay clone were generated by cotransfection of HLA-DRB51 MJS cells (14) with the cyto-EBNA1, empty-IRES-GFP, or vIRF3-IRES-GFP expression plasmid.
Retrovirus and transduction. Retroviral constructs were engineered by cloning vIRF3 or HLA-B81 as a control into the pLZRS retroviral vector. Immediately downstream from the inserted gene was an internal ribosome entry site (IRES) and the marker gene, either truncated nerve growth factor (⌬NGFR) or green fluorescent protein (GFP). Vesicular stomatitis virus-pseudotyped retrovirus particles were produced in GP2-293 cells cotransfected with the pVSV-G envelope vector. Virus in the culture supernatant at 72 h was concentrated by ultracentrifugation (15 ml) and used to infect 5 ϫ 10 5 target cells overnight. Lymphoblastoid cell lines (LCLs) were established from healthy donor B cells using the B95.8 strain of EBV. Both LCLs and PELs were maintained in RPMI 1640 medium (Gibco BRL) supplemented with 10% FCS. For the retrovirus that coexpresses NGFR, the transduced LCL or PEL cells were magnetically sorted using magnetically activated cell sorting NGFR-specific beads as directed by the manufacturer (Miltenyi Biotech).
Stable transfection and establishment of pvIRF3-tet cell lines. A derivative of the doxycycline (DOX)-dependent expression vector pRTS-1 (20) was kindly provided by J. Mautner, Munich, Germany; vIRF3 or the reverse vIRF3 sequence as a control was introduced into the vector by standard DNA cloning procedures to create vectors pRTS-CD2-vIRF3 and pRTS-CD2-control, respectively. The pRTS-CD2-vIRF3 or pRTS-CD2-control vector was introduced into an EBV-negative derivative of the Akata BL line, Akata-A3, by electroporation of 10 g plasmid DNA into 10 7 cells in Opti-MEM medium (Invitrogen) at 280 V and 960 F using a Bio-Rad electroporation apparatus. Transfected cells were cultured in RPMI 1640 medium supplemented with 10% FCS. After 24 h, the transfected cell population was enriched by staining with OX34 antibody to rat CD2 and positively selected by magnetic cell sorting with antimouse IgG2a/b microbeads and LS columns (Miltenyi Biotech) according to the manufacturer's guidelines. Cells were thereafter expanded and maintained in RPMI 1640 medium supplemented with 10% FCS. Expression of vIRF3 was induced by addition of titrated doses of DOX, and the induced cells were positively selected by magnetic cell sorting with anti-NGFR microbeads and LS columns (Miltenyi Biotech). The purity of the sorted cells was checked by flow cytometry.
Flow cytometry analysis of cell surface MHC molecules. Cell surface expression of MHC-II DR or NGFR on viable cells was determined by staining with phycoerythrin (PE)-conjugated anti-DR (Biolegend) or fluorescein isothiocyanate (FITC)-conjugated anti-NGFR (Biolegend). Cell surface expression of MHC-II DQ on viable cells was determined by staining with anti-DQ (Biolegend), followed by allophycocyanin (APC)-conjugated anti-mouse IgG (Biolegend). Stained cells were analyzed on a BD Accuri C6 flow cytometer, and the data were processed using FlowJo software (Tree Star).
Western blotting. Goat antibodies to calregulin, mouse anti-DR␣, mouse anti-DR␤, mouse anti-DM␣, rat anti-LANA-1, and rabbit anti-CIITA were purchased from Santa Cruz Biotechnology. Mouse anti-KSHV-encoded vIRF3 was purchased from Novus Biologicals. Total cell lysates were denatured in reducing sample buffer (final concentrations, 2% sodium dodecyl sulfate [SDS], 72.5 mM Tris-HCl, pH 6.8, 10% glycerol, 0.2 M sodium 2-mercaptoethane-sulfonate, 0.002% bromophenol blue) and then sonicated and heated to 100°C for 5 min. Solubilized proteins equivalent to 10 5 cells/20-l sample were separated by SDS-polyacrylamide gel electrophoresis (PAGE) on 4 to 12% acrylamide gradient bis-Tris NuPage minigels with MOPS (morpholinepropanesulfonic acid) running buffer (Invitrogen). Following electroblotting to polyvinylidene difluoride membranes, immunoblotting with specific primary antibodies followed by detection with appropriate alkaline phosphatase-conjugated secondary antibodies and a CDP-Star chemiluminescence detection kit (Tropix; Applied Biosystems) was performed as previously described (21) .
T cell function assays. T cells were grown in 10% FCS in RPMI 1640 medium supplemented with 30% supernatant from the interleukin-2 (IL-2)-producing MLA-144 cell line and 50 U/ml recombinant IL-2. The effector CD4 ϩ T cell clones SNP (specific for amino acids 474 to 493 of EBV EBNA1 and restricted through DRB51), LAP/LRS (specific for amino acids 191 to 210 of KSHV LANA1 and restricted through DQ6), and LAP (specific for amino acids 191 to 205 of KSHV LANA1 and restricted through DP1) were generated as described elsewhere (16, 18) . The effector CD8 ϩ T cell clone CLG (specific for amino acids 426 to 434 of LMP2 and restricted through MHC-I A0201) was described elsewhere (22) . The capacity of CD4 ϩ and CD8 ϩ T cell clones to recognize target LCLs, MJS cells, or BCBL-1 cells was measured by a gamma interferon (IFN-␥)-specific enzyme-linked immunosorbent assay (ELISA). Briefly, 10 4 effector T cells were incubated for 18 h at 37°C in V-bottom microtest plate wells with 10 5 target cells, before assaying the supernatants for IFN-␥ release by ELISA (Endogen) in accordance with the manufacturer's recommended protocol. Antigen-sensitized targets were either incubated with peptides for 1 h or cultured for 18 h with LANA protein preparations (16) in AIM-V medium (Invitrogen).
QRT-PCR assay. Total RNA was isolated from cultured cell lines using a Qiagen RNeasy kit and treated with DNase I (Turbo DNA-free kit; Ambion). Quantitative RT-PCR (QRT-PCR) assays for CIITA, DRA, DRB, DQA, DPA, DMA, DOA, CD74, HLA-A, and PGK were performed with TaqMan gene expression assays (Applied Biosystems), duplexed with GAPDH (glyceraldehyde-3-phosphate dehydrogenase) assays for normalization.
RESULTS
vIRF3 expression level is related to MHC-II antigen presentation in PELs. In a previous paper (16), we speculated that the poor recognition of PELs by MHC-II-matched LANA-specific CD4 T cells was due to the expression of vIRF3. On closer examination of the VG-1 PEL line (23), we observed normal levels of MHC class II cell surface receptor (both MHC-II DR and MHC-II DQ) expression in a small subpopulation of cells (high DR DQ population) (Fig. 1A) . Flow cytometry cell sorting of MHC-II DR-stained VG-1 cells enabled the isolation of two populations: one with high DR expression and the other with low DR expression (Fig. 1B) . These two populations of VG-1 cells were assayed for recognition by MHC-II-matched LANA-specific CD4 T cells restricted through DQ6 (LAP/LRS peptide specific) or DP1 (LAP peptide specific) (16) . Recognition was measured from the release of IFN-␥ from the effector T cells. Little or no recognition of VG-1 cells with low DR expression was observed, but there was clear recognition of VG-1 cells with high DR expression that was in some cases comparable to the recognition of control B cells pulsed with synthetic target peptide (Fig. 1C) . Aliquots of cells from replicate experiments were analyzed by immunoblotting, and band intensities were quantified. The mean expression of vIRF3 expression in VG-1 cells with high DR expression compared with that in VG-1 cells with low DR expression was 51.5% Ϯ 6.3% (Fig. 1D) . Expression of LANA showed less of a reduction, with a mean expression of 75.5% Ϯ 3.4% in VG-1 cells with high DR expression compared with that for VG-1 cells with low DR expression. Similar results were obtained with another PEL cell line, BC-1 (data not shown).
These data extend previously published results to provide strong support for the idea that vIRF3 expression level is indeed related to MHC-II antigen presentation in PELs.
vIRF3 can modulate MHC-II antigen presentation in MJS cells. A potential mechanistic explanation for the inverse correlation between vIRF3 and MHC-II antigen presentation in PELs might be found in the recent demonstration that vIRF3 inhibits the promoters of CIITA, leading to inhibition of the transcription and translation of MHC-II elements (17) . To investigate this possibility in more detail, we tested the effect of vIRF3 on MHC-II antigen presentation using CD4 T cell effectors in a functional assay previously developed in our Birmingham laboratories (14) . MJS melanoma cells expressing MHC-II DRB51 were transfected with a cyto-EBNA1 expression plasmid together with an empty IRES-GFP vector or with a vIRF3-IRES-GFP vector expressing vIRF3. The cultures were then cocultured with MHC-II DRB51-restricted CD4 T cells specific for the SNP EBNA1-derived peptide, and T cell recognition was measured from the release of IFN-␥ from the effector cells. Mock-transfected cells were not recognized, but good recognition was seen with target cells cotransfected with cyto-EBNA1 and the control IRES-GFP vector ( Fig. 2A) . A substantial 50% reduction in recognition of cyto-EBNA1 was observed when the target cells were cotransfected with vIRF3 ( Fig. 2A) .
Replicate aliquots of cells analyzed by immunoblotting confirmed expression of vIRF3 in the cultures transfected with the vIRF3-GFP plasmid, in which about 10% of the cells became GFP positive (GFP ϩ ), and the levels of EBNA1 were similar between the cells cotransfected with cyto-EBNA1 and IRES-GFP or vIRF3-GFP (Fig. 2B) . Two-color flow cytometry analysis of viable cells stained for surface MHC-II DR suggested that vIRF3 caused a small but reproducible reduction (about 15%) in the level of cell surface DR molecules on GFP ؉ cells compared to the expression on untransfected GFP-negative (GFP Ϫ ) cells in the same cultures (Fig. 2C) . In four independent experiments, the mean expression of surface MHC-II DR in the GFP ϩ cells compared to untransfected GFP Ϫ cells was 85.8% Ϯ 7.5% (P ϭ 0.0089). vIRF3 can inhibit CIITA transcription and reduce surface MHC-II DR expression, but with slow kinetics. The key finding from the transient-transfection experiments whose results are shown in Fig. 2 was that a substantial reduction of CD4 T cell recognition was observed with only a very small reduction of cell surface MHC-II DR expression. As vIRF3 is a latent gene that is constitutively expressed in KSHV-positive PELs (24, 25) , it is physiologically relevant to also check the phenotype of vIRF3 at later time points. To this end, we generated a bicistronic retrovirus, pLZRS-vIRF3-IRES-NGFR, that coexpresses vIRF3 with a truncated inactive NGFR, which was used as a marker to identify and purify the transduced population. The MJS cells were transduced with control, LZRS-B81-IRES-NGFR, or LZRS-vIRF3-IRES-NGFR retroviruses, and surface MHC-II expression was monitored through two-color flow cytometry staining of surface MHC-II DR and NGFR as a surrogate marker of vIRF3 expression (Fig. 3A) . At day 2, the relative fluorescence intensity of surface DR staining on the NGFR-positive (NGFR ϩ ) (vIRF3-positive [vIRF3 ϩ ]) cells was about 60% compared to that of untransduced NGFGR-negative (NGFR Ϫ ) (vIRF3-negative [vIRF3 Ϫ ]) cells in the same culture (Fig. 3A, left) . However, by day 5, the surface DR expression was substantially reduced to about 13% by vIRF3 (Fig. 3A,  middle) , and at day 7, the surface DR expression was reduced to about 7% on NGFR ϩ (vIRF3 the control retrovirus-and vIRF3 retrovirus-transduced cells in these experiments were purified by NGFR sorting at each time point after transduction. QRT-PCR assays with total mRNA isolated from these samples showed that vIRF3 can effectively inhibit the transcription of CIITA and MHC-II elements DR and DP as early as 2 days after transduction ( Fig. 3C and D) . More extensive transcriptional analyses on the day 7 samples showed that the transcripts of CIITA and all MHC-II elements tested (including DRA, DRB, DPA, DMA, DOA, and CD74) were significantly downregulated following vIRF3 expression in MJS cells (P Ͻ 0.01) (Fig. 3D) .
Immunoblot analysis of cell lysates at day 7 confirmed the expression of vIRF3 and a corresponding reduction in total cellular DR␣ protein expression in the cell lysates from vIRF3-transduced cells compared to control retrovirus-transduced cells (Fig. 3E) .
Together, these data show that vIRF3 can substantially reduce total and surface MHC-II DR protein expression but that it does so with much slower kinetics than the more immediate inhibition of CIITA expression and subsequent impairment of MHC-II element transcription.
Ectopic expression of CIITA can partly abolish surface MHC-II DR downregulation by vIRF3. To investigate whether the delayed substantial reduction of surface MHC-II DR protein expression in MJS cells was due to the inhibition of CIITA transcription, we generated an MJS cell line with ectopic overexpression of CIITA driven by a retrovirus promoter. It was confirmed by immunoblotting that CIITA was overexpressed in the CIITAexpressing MJS cell line, which resulted in a small increase of the already high levels of MHC-II DR expression in MJS cells that was evident by flow cytometry (Fig. 4A) . In the next set of experiments, MJS cells and CIITA-expressing MJS cells were transduced with control/GFP or vIRF3/GFP bicistronic retroviruses to examine whether constitutive overexpression of CTIIA might affect the ability of vIRF3 to downregulate surface MHC-II DR expression. Expression of vIRF3 was confirmed by immunoblotting of cell lysates (Fig. 4C) . Flow cytometry revealed that when maximal inhibition of MHC-II DR expression by vIRF3 was achieved (i.e., by day 9 in Fig. 4B ), the level of surface DR on vIRF3/GFP ϩ -expressing control MJS cells was reduced to about 11% of the expression in GFP Ϫ , non-vIRF3-expressing MJS cells, whereas in CIITA-expressing MJS cells, the expression of vIRF3 reduced the level of surface DR expression to 28% of the level of expression in nonvIRF3-expressing cells. Reproducibly, the constitutive overexpression of CTIIA in MJS cells resulted in about 3 times more surface DR in vIRF3-expressing cells.
These data are consistent with the reduction of surface MHC-II DR expression and modulation of MHC-II antigen presentation by vIRF3 being partially due to the inhibition of the transcription of CIITA and the fact that the delayed effect on protein expression is due to the known long half-life of MHC-II molecules. However, it is important to note that the reduction of surface MHC-II DR expression cannot be fully reversed by the ectopic overexpression of CIITA.
vIRF3 inhibits CIITA transcription in a B cell line. All the work described above was carried out in the MJS cell model, but in the context of PELs, it would be physiologically more relevant to examine the behavior of vIRF3 in B cells. To this end, we generated from the EBV-negative Akata-A3 Burkitt lymphoma line transfectants with a DOX-inducible vIRF3-expressing vector, pRTS-CD2-vIRF3. The vIRF3 gene and an NGFR-IRES-GFP sequence were regulated by a bidirectional DOX-regulated promoter which allows the purification of vIRF3-expressing cells following DOX induction. By titrating the concentration of DOX, at 2 ng/ml we achieved expression levels of vIRF3 that were similar to those in PELs (Fig. 5A) . As we know from the previous experiments in MJS cells that vIRF3 affects MHC-II with slow kinetics, we harvested the B cells at 7 to 11 days postinduction. Two-color flow cytometry analysis of viable cells stained for surface MHC-II DR suggested that vIRF3 reduced the level of cell surface DR molecules only slightly but reproducibly by about 15% (Fig. 5B) . Immunoblot analysis of purified GFP/NGFR ϩ cells confirmed the expression of vIRF3 in the cells containing the vIRF3 vector, but the levels of DR␣, DR␤, DM␣, and the MHC-I heavy chain were not noticeably altered by vIRF3 (Fig. 5C ). Analysis of RNA by QRT-PCR showed that the transcripts of CIITA and, with the exception of MHC-II DMA, all of the MHC-II elements tested were substantially reduced (P Ͻ 0.01) following vIRF3 expression compared with the levels in control Akata-A3 cells (Fig. 5D) .
Therefore, physiological levels of vIRF3 do effectively inhibit CIITA and MHC-II element transcription in B cells but do not necessarily impact the levels of MHC-II protein molecules in these cells in the time scale of this experiment. firmed by immunoblotting, although it was clear that the levels were lower than those of vIRF3 expression in PELs (Fig. 6A) . Also, there was no obvious difference in total cellular and surface MHC-II DR expression between the control LCLs and vIRF3-expressing LCLs (Fig. 6A) .
To investigate the effect of vIRF3 on MHC-II antigen presentation, control LCLs and vIRF3-expressing LCLs were fed LANA protein and then cocultured with MHC-II-matched-allele (DQ6)-restricted LAP/LRS LANA-specific CD4 T cells. T cell recognition was measured from the release of IFN-␥ from the effector cells, and peptide-pulsed target cells served as controls. There was no recognition of either type of LCL pulsed with control protein.
Good recognition was seen with both LCLs when fed with LANA protein, but there was an approximately 50% reduction of T cell recognition in the LANA-fed vIRF3-expressing LCLs compared with that in control LCLs (Fig. 6B) . Furthermore, this reduction was not observed when the LCLs were pulsed with specific LANA peptides. In additional control experiments, the recognition by HLA-A0201-restricted CD8 T cells specific for the GLC peptide of EBV LMP2 did not differ between the control and vIRF3-expressing LCLs (Fig. 6C) .
vIRF3 modulates MHC-II antigen presentation in BCBL-1 cells independently of CIITA inhibition. In our previous study, we observed that one unique PEL line, BCBL-1, can be recognized by LANA-specific CD4 T cells and correlated with the lowest level of vIRF3 expression (16) . To investigate whether overexpression of vIRF3 in this PEL can modulate MHC-II antigen presentation, we transduced BCBL-1 cells with control pLZRS-B81-IRES-NGFR retrovirus and pLZRS-vIRF3-IRES-NGFR retrovirus. At 7 to 10 days postinduction, these cells were analyzed in various assays. Two-color flow cytometry analysis of viable cells stained for surface MHC-II DR showed that vIRF3 reduced the level of cell surface MHC-II DR expression by about 50% on NGFR/vIRF3 ϩ cells compared to the level of expression on NGFR/vIRF3 Ϫ cells in the same cultures (Fig. 7A) . Immunoblot analysis of pure populations of vIRF3-expressing BCBL-1 cells confirmed the overexpression of vIRF3 in the vIRF3-expressing BCBL-1 cells compared with the level of expression in control BCBL-1 cells and a concomitant small level of reduction of total MHC-II DR expression following vIRF3 expression (Fig. 7B) .
To investigate whether this downregulation of MHC-II DR expression is sufficient to modulate MHC-II antigen presentation, BCBL-1 control and vIRF3-expressing BCBL-1 cells were cocultured with MHC-II-matched-allele (DQ6)-restricted LAP/LRS LANA-specific CD4 T cells, and T cell recognition was measured from the release of IFN-␥ from the effector cells. The result showed that the recognition by CD4 T cells was substantially reduced with vIRF3-expressing BCBL-1 cells compared with that achieved with control BCBL-1 cells (Fig. 7C) .
Finally, the effect of vIRF3 overexpression on the transcription of CIITA and MHC-II elements was investigated through QRT-PCR assays carried out on the total RNA isolated from the NGFRsorted population. As shown in Fig. 7D , while the transcription of most of the MHC-II elements was reduced following the overexpression of vIRF3 in BCBL-1 cells, there was no reduction in the transcription of CIITA by vIRF3.
Therefore, in a PEL background, vIRF3 can reduce the surface MHC-II DR expression and inhibit MHC-II antigen presentation through a CIITA-independent mechanism. 
DISCUSSION
Consistent with a recent report that vIRF3 has the potential to inhibit the transcription of CIITA and the subsequent expression of MHC-II genes (17), we have now shown, using antigen-specific recognition by CD4 T cells, that vIRF3 can modulate the MHC-II antigen presentation function in melanoma cells, B cells, and PEL cells. These functional assays revealed a level of complexity that was not evident from the previous biochemical observations. Thus, while we confirmed that vIRF3 can indeed downregulate MHC-II DR expression, the kinetics of this effect were slow and were preceded by a substantial impairment in presentation of antigen to CD4 effector T cells. Furthermore, while CIITA might contribute to the downregulation of MHC-II molecules under some circumstances, our combined data from different cell lines and particularly PEL lines show that the modulation of MHC-II antigen presentation by vIRF3 may be mediated predominantly through CIITA-independent mechanisms.
CIITA is a master regulator of the expression of MHC-II elements, including HLA-DR, HLA-DQ, HLA-DP, HLA-DM, HLA-DO, and invariant chain/CD74. It is a transcriptional coactivator that lacks an intrinsic DNA-binding function. It enhances the transcription of MHC-II genes through interaction with transcription regulatory proteins, forming a stable enhanceosome that can bind to the regulatory module of MHC-II promoters (26, 27 ). CIITA appears to be a vulnerable target for viral modulation of MHC-II gene expression (17, 28) . Li et al. demonstrated that the EBV-encoded immediate early protein BZLF1, which is the mas- ter regulator of the EBV lytic cycle, can bind to the CIITA promoter and strongly inhibit the transcription and constitutive expression of CIITA molecules (28) . MHC-II molecules are constitutively expressed on professional antigen-presenting cells, which express CTIIA, but the expression can also be induced on other cells by IFN-␥ through the induced transcription of CIITA. In this context, HCMV infection of U373 MG cells reduced the level of IFN-␥-induced CIITA transcripts by more than 10-fold, with a concordant inhibition of induced MHC-II DR synthesis (29) . Similarly, varicella-zoster virus infection of human foreskin fibroblasts can prevent IFN-␥-induced CIITA expression and expression of MHC-II molecules (30) . KSHV vIRF3 can inhibit both constitutive and IFN-␥-induced CIITA transcription (17) , but in the light of the findings of our present work, it is possible that the action of vIRF3 on CTIIA might be most important for inhibiting the IFN-␥-induced CTIIA.
As MHC-II molecules have a long half-life compared to MHC-I molecules (31), inhibition of CIITA and thus MHC-II gene transcription would not be expected to have a rapid effect on preexisting MHC-II protein levels. Indeed, both in a previous study by Schmidt and colleagues (17) and in the present work, a relatively small downregulation of MHC-II protein was observed 48 h after expression of vIRF3 vectors. Interestingly, over a longer time course in the MJS cell line, inhibition of transcription was observed to be a very effective mechanism to modulate the expression of MHC-II proteins; after 5 to 7 days of expression of vIRF3, expression of the MHC-II DR protein on the cell surface was reduced by more than 10-fold (Fig. 3B) . As vIRF3 is a KSHV latent protein that is consistently expressed in the KSHV-positive PEL line (25), we postulate that the effect of vIRF3 on MHC-II transcription, whether it is via CTIIA or not, is a major factor responsible for maintaining the phenotype of little or no MHC-II expression in these tumors. In our experiments with B cells, expression of vIRF3 had no effect (Akata-A3) or little effect (BCBL-1) on total MHC-II DR expression. One possible explanation for this could be that MHC-II DR is even more stable in B cells than MJS and epithelial cells, so that downregulation of total MHC-II DR would require a longer time; it is difficult to test this experimentally, as we found vIRF3 to be toxic over prolonged periods in these cells. Another possibility, which is not mutually exclusive, is that transcriptional regulation of MHC-II is not the major mechanism by which vIRF3 interferes with antigen presentation in B cells.
Three lines of evidence indicate that vIRF3 effects a CIITAindependent mechanism to modulate MHC-II antigen presentation. First, vIRF3 mediated significant downregulation of MHC-II DR in CIITA-expressing MJS cells that ectopically overexpress CIITA from a retroviral vector (Fig. 4) . Second, EBV-transformed LCLs stably expressing vIRF3 showed a reduced ability to present MHC-II/peptide to CD4 T cells, even though no inhibition of CIITA transcripts was detected by QRT-PCR (data not shown). Finally, ectopic overexpression of vIRF3 in the BCBL-1 PEL line did not alter the levels of CIITA transcripts but did reduce MHC-II transcription, expression, and recognition by CD4 T cells (Fig. 7) . This CIITA-independent inhibition of the transcription of MHC-II elements in BCBL-1 cells by vIRF3 sheds some light on the nature of the mechanism, pointing to an alternative regulation of MHC-II element transcription. However, the data obtained from LCLs (Fig. 6 ) suggest that this is not the only CIITA-independent mechanism, as here vIRF3 inhibited the MHC-II antigen presentation function in the absence of any effect on MHC-II expression. The utilization of dual molecular mechanisms impacting antigen presentation is not unique to vIRF3. For example, EBV-encoded BZLF1 inhibits CIITA transcription (28) but also downregulates the surface expression of CD74 and T cell recognition in a CIITA-independent manner (14) .
It is important to note from both this study and our previous work that surface MHC-II expression levels do not necessarily correlate with the MHC-II antigen presentation function. In one sense, this is unsurprising, as viral modulation of antigen presentation is known to target multiple points in the processing pathways, some of which might qualitatively alter the MHC/peptide complexes without necessarily affecting the quantity of MHC-II molecules at the cell surface. Functional T cell assays are exquisitely sensitive to such qualitative changes that are not detected in routine biochemical assays. In the present study, there was a substantial reduction in CD4 T cell recognition at 2 days after expression of vIRF3, when surface MHC-II levels were barely affected. Although this observation might be less relevant to the latent expression pattern of vIRF3 in KSHV-positive tumor cells, where the longer-term effects of CTIIA inhibition may be effective, we speculate that it could well be important in the early stage of KSHV infection of nonmalignant cells to prevent their recognition and elimination by KSHV-specific CD4 T cells.
T-cell responses to KSHV-encoded latent antigens and lytic antigens have been identified in both healthy immunocompetent donors and immunocompromised patients (32) (33) (34) (35) (36) (37) . Although generally weak, KSHV-specific CD8 T cells responses are more frequent, diverse, and strong in asymptomatic KSHV-infected patients than Kaposi's sarcoma patients (38) . Very recently, Sabbah et al. found that the responses in healthy KSHV-infected donors to the KSHV latent antigens were most frequently directed to LANAderived peptides (16) . Interestingly, most of the LANA-specific T cell clones generated were CD4 lymphocytes. It might therefore be speculated that in order to establish a persistent infection (and also to generate malignancies), it is necessary for KSHV-infected cells to evade not only CD8 responses, for which various mechanisms have been identified (7, 8, 21, 39, 40) , but also CD4 T cell responses.
Generally, effector CD4 T cells can be generated during both chronic and acute infection with herpesviruses and are important for controlling the infection through both cytotoxic and cytokinedependent mechanisms. Many herpesviruses encode multiple immunoevasins which together target MHC-II processing and presentation pathways. There is now accumulating evidence to suggest that the same may be true for KSHV. A recent study showed that KSHV infection of human primary endothelial cells inhibits IFN-␥-induced expression of the MHC-II molecule at the transcriptional level via soluble mediators, including cytokines released from KSHV-infected endothelial cells (41) . This is likely to be a mechanism separate from that identified in the present study, as we have observed the effects of vIRF3 on T cell recognition in the absence of effects on MHC-II expression.
Multiple functions have been ascribed to vIRF3. For example, it binds to IRF5 and inhibits interferon-responsive transcription (42) ; it can potently inhibit the transcription induced by overexpression of p53 and, consequently, inhibit apoptosis (25) ; it has been reported to be associated with the c-myc suppressor, which in turn stimulates c-myc-mediated transcription and consequently contributes to B cell growth (43) ; and it can specifically interact with the hypoxia-inducible factor 1 (HIF-1) alpha sub-unit, leading to HIF-1 stabilization and transcriptional activation (44) . Ultimately, vIRF-3 was shown to be indispensable to the proliferation of PEL cells in culture and has been proposed to be a predominant factor in the pathogenesis of PEL cells (45) . Indeed, in our study we tried to knock down vIRF3 expression in PEL cells with small interfering RNA or short hairpin RNA in an attempt to reverse the immune-modulatory phenotype of vIRF3, but we were unable to generate a stable line with lower vIRF3 expression (data not shown). To circumvent this problem, we took advantage of the fact that some PEL lines contained a small population of cells with high surface MHC-II expression and lower vIRF3 expression (Fig. 1) . Interestingly, the variations in MHC-II and vIRF3 expression were dynamic, as when the high-and low-expressing sorted populations were returned to culture, they reverted to the mean level of expression within 7 days (data not shown). This phenomenon probably reflects the fact that a critical level of vIRF3 expression is required for continued growth of the cells. However, if the mechanism of vIRF3 regulation were to be elucidated, it might be targeted therapeutically in PELs; reduced vIRF3 expression might both impair their growth and/or survival and also render the tumors susceptible to LANA-specific CD4 effector T cells.
In summary, this study has characterized aspects of the MHC-II immune modulation function of vIRF3 that extend our understanding of the roles of this protein in infection of nonmalignant target cells in asymptomatic persistence and in the KSHVassociated malignancy PEL.
